EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say

The US Food and Drug Administration has shelved a priority review voucher pilot program championed by Commissioner Marty Makary, according to exclusive reporting from Reuters citing unnamed sources. The program, described as a flagship fast-track initiative, would have allowed drugmakers to receive expedited reviews for certain medications through a voucher system. The Independent characterizes the move as the FDA "quietly" shelving what it calls "Trump's flagship drug fast-track program" amid reports of agency chaos. TradingView notes the program was a "fast-track priority voucher pilot program." Pharmaphorum frames the question as whether "Makary's priority review vouchers" are "about to be canned." STAT includes the FDA shelving in its "Pharmalittle" roundup alongside other pharmaceutical industry news including a Canadian importer arrest.

The coverage emphasizes the program's association with Commissioner Makary and its status as a priority review voucher mechanism designed to accelerate drug approvals. Reuters' exclusive reporting cites sources saying the FDA has shelved the program, though the coverage does not specify the reasons cited by those sources or the exact timeline for the decision. The Independent's framing connects the shelving to broader reports of agency chaos, while pharmaphorum's headline poses the development as a question about the program's future. TradingView and STAT provide additional confirmation of the Reuters exclusive. None of the headlines specify which drugs or therapeutic areas would have been affected by the voucher program, nor do they detail the program's specific structure or eligibility criteria.

The coverage does not specify whether Makary's pilot program would have expanded existing voucher authorities or created a new framework. The Independent's reference to "Trump's flagship drug fast-track program" suggests a connection to the prior administration, though the coverage does not elaborate on the program's origins or whether it was formally proposed through rulemaking or operated as an internal pilot. The shelving comes amid what The Independent describes as reports of agency chaos, though the nature of those reports is not detailed in the headlines.

Based on the coverage, key developments to watch include whether the FDA issues an official statement confirming or clarifying the shelving, whether Commissioner Makary or other agency officials address the program's status publicly, and whether congressional oversight committees request information about the decision. The coverage does not indicate whether the program was formally announced before being shelved, whether any vouchers had been awarded or applications received, or whether the decision is reversible. Pharmaphorum's questioning headline suggests industry uncertainty about the program's definitive status. STAT's inclusion in a broader industry roundup indicates the development is being tracked alongside other regulatory and enforcement actions in the pharmaceutical sector.